According to Figure 9, PDE4A expression has specific impacts on the treatment response of trametinib (R2 = −0.28, p < 0.001), docetaxel (R2 = 0.22, p < 0.001), bleomycin (R2 = −0.25, p < 0.001), cisplatin (R2 = 0.42, p < 0.001), temozolomide (R2 = 0.39, p < 0.001), vinorelbine (R2 = 0.25, p < 0.001), rapamycin (R2 = −0.27, p < 0.001), vinblastine (R2 = 0.26, p < 0.001), pyrimethamine (R2 = −0.28, p < 0.001), and crizotinib (R2 = −0.24, p < 0.001) during treatment of NSCLC. The gene discussed is PDE4A; the disease is non-small cell lung carcinoma.